Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Small Molecule Compounds That Inhibit Antioxidant Response Gene Expression in an Inducer-Dependent Manner.

Edwards MR, Liu G, De S, Sourimant J, Pietzsch C, Johnson B, Amarasinghe GK, Leung DW, Bukreyev A, Plemper RK, Aron Z, Bowlin TL, Moir DT, Basler CF.

ACS Infect Dis. 2020 Jan 15. doi: 10.1021/acsinfecdis.9b00416. [Epub ahead of print]

PMID:
31899866
2.

A narrative review of long-term central venous access devices for the intensivist.

Moir D, Bodenham A.

J Intensive Care Soc. 2018 Aug;19(3):236-246. doi: 10.1177/1751143717741249. Epub 2017 Dec 12. Review.

3.

Calibration of two compact permanent magnet spectrometers for high current electron linear induction accelerators.

Burris-Mog TJ, Chavez MA, Espy MA, Manard MJ, Moir DC, Schillig JB, Trainham R, Volegov PL.

Rev Sci Instrum. 2018 Jul;89(7):073303. doi: 10.1063/1.5029837.

PMID:
30068099
4.

Refractory hyperparathyroidism with a T3 bony lesion-differential diagnoses.

Chan DWC, Moir D, Standish R, Kotowicz MA.

Oxf Med Case Reports. 2018 Mar 20;2018(3):omx109. doi: 10.1093/omcr/omx109. eCollection 2018 Mar.

5.

Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.

Berube BJ, Murphy KR, Torhan MC, Bowlin NO, Williams JD, Bowlin TL, Moir DT, Hauser AR.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01202-17. doi: 10.1128/AAC.01202-17. Print 2017 Nov.

6.

A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface.

Liu G, Nash PJ, Johnson B, Pietzsch C, Ilagan MX, Bukreyev A, Basler CF, Bowlin TL, Moir DT, Leung DW, Amarasinghe GK.

ACS Infect Dis. 2017 Mar 10;3(3):190-198. doi: 10.1021/acsinfecdis.6b00209. Epub 2017 Feb 9.

7.

DNA Targeting as a Likely Mechanism Underlying the Antibacterial Activity of Synthetic Bis-Indole Antibiotics.

Opperman TJ, Kwasny SM, Li JB, Lewis MA, Aiello D, Williams JD, Peet NP, Moir DT, Bowlin TL, Long EC.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7067-7076. Print 2016 Dec.

8.

Beyond Antibiotics: New Therapeutic Approaches for Bacterial Infections.

Hauser AR, Mecsas J, Moir DT.

Clin Infect Dis. 2016 Jul 1;63(1):89-95. doi: 10.1093/cid/ciw200. Epub 2016 Mar 29.

9.

Sweat chloride concentrations in children with Idiopathic Nephrotic Syndrome.

Guglani L, Moir D, Jain A.

Pediatr Pulmonol. 2016 Jan;51(1):49-52. doi: 10.1002/ppul.23213. Epub 2015 Aug 26.

PMID:
26309139
10.

Novel Small Molecule Entry Inhibitors of Ebola Virus.

Basu A, Mills DM, Mitchell D, Ndungo E, Williams JD, Herbert AS, Dye JM, Moir DT, Chandran K, Patterson JL, Rong L, Bowlin TL.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S425-34. doi: 10.1093/infdis/jiv223. Epub 2015 Jul 22.

11.

Discovery of bacterial fatty acid synthase type II inhibitors using a novel cellular bioluminescent reporter assay.

Wallace J, Bowlin NO, Mills DM, Saenkham P, Kwasny SM, Opperman TJ, Williams JD, Rock CO, Bowlin TL, Moir DT.

Antimicrob Agents Chemother. 2015 Sep;59(9):5775-87. doi: 10.1128/AAC.00686-15. Epub 2015 Jul 13.

12.

Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review.

Black C, Tagiyeva-Milne N, Helms P, Moir D.

Br J Clin Pharmacol. 2015 Oct;80(4):844-54. doi: 10.1111/bcp.12645. Epub 2015 May 28. Review.

13.

Squamoid eccrine ductal carcinoma of the scalp.

Chan H, Howard V, Moir D, Dyall-Smith D.

Australas J Dermatol. 2016 Aug;57(3):e117-9. doi: 10.1111/ajd.12309. Epub 2015 Mar 6. Review.

PMID:
25752474
14.

An investigation into exposure of pigs to lead from contaminated zinc oxide in 2007-2008.

MacLachlan Dj, Dixon F, Klim E, Lutze J, Matisons M, Moir D, Smith G.

Aust Vet J. 2015 Mar;93(3):72-8. doi: 10.1111/avj.12281.

PMID:
25708790
15.

Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).

Williams JD, Torhan MC, Neelagiri VR, Brown C, Bowlin NO, Di M, McCarthy CT, Aiello D, Peet NP, Bowlin TL, Moir DT.

Bioorg Med Chem. 2015 Mar 1;23(5):1027-43. doi: 10.1016/j.bmc.2015.01.011. Epub 2015 Jan 13.

16.

Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.

Bowlin NO, Williams JD, Knoten CA, Torhan MC, Tashjian TF, Li B, Aiello D, Mecsas J, Hauser AR, Peet NP, Bowlin TL, Moir DT.

Antimicrob Agents Chemother. 2014;58(4):2211-20. doi: 10.1128/AAC.02795-13. Epub 2014 Jan 27.

17.

Potent and broad-spectrum antibacterial activity of indole-based bisamidine antibiotics: synthesis and SAR of novel analogs of MBX 1066 and MBX 1090.

Williams JD, Nguyen ST, Gu S, Ding X, Butler MM, Tashjian TF, Opperman TJ, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.

Bioorg Med Chem. 2013 Dec 15;21(24):7790-806. doi: 10.1016/j.bmc.2013.10.014. Epub 2013 Oct 25.

18.

New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.

Basu A, Antanasijevic A, Wang M, Li B, Mills DM, Ames JA, Nash PJ, Williams JD, Peet NP, Moir DT, Prichard MN, Keith KA, Barnard DL, Caffrey M, Rong L, Bowlin TL.

J Virol. 2014 Feb;88(3):1447-60. doi: 10.1128/JVI.01225-13. Epub 2013 Nov 6.

19.

A look at the grouping effect on population-level risk assessment of radon-induced lung cancer.

Chen J, Moir D.

Glob J Health Sci. 2013 Jul 21;5(6):1-11. doi: 10.5539/gjhs.v5n6p1.

20.

Characterization of the Burkholderia thailandensis SOS response by using whole-transcriptome shotgun sequencing.

Ulrich RL, Deshazer D, Kenny TA, Ulrich MP, Moravusova A, Opperman T, Bavari S, Bowlin TL, Moir DT, Panchal RG.

Appl Environ Microbiol. 2013 Oct;79(19):5830-43. doi: 10.1128/AEM.00538-13. Epub 2013 Jul 19.

21.

Optimization of a novel potent and selective bacterial DNA helicase inhibitor scaffold from a high throughput screening hit.

Li B, Pai R, Aiello D, Di M, Barnes MH, Peet NP, Bowlin TL, Moir DT.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3481-6. doi: 10.1016/j.bmcl.2013.04.055. Epub 2013 Apr 30.

22.

An ecological study of cancer incidence in Port Hope, Ontario from 1992 to 2007.

Chen J, Moir D, Lane R, Thompson P.

J Radiol Prot. 2013 Mar;33(1):227-42. doi: 10.1088/0952-4746/33/1/227. Epub 2013 Jan 16.

PMID:
23324463
23.

Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: chemical optimization, biological evaluation, and antibacterial activities.

Li B, Pai R, Di M, Aiello D, Barnes MH, Butler MM, Tashjian TF, Peet NP, Bowlin TL, Moir DT.

J Med Chem. 2012 Dec 27;55(24):10896-908. doi: 10.1021/jm300922h. Epub 2012 Dec 11.

24.

Bis-imidazolinylindoles are active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Mycobacterium tuberculosis.

Panchal RG, Lane D, Boshoff HI, Butler MM, Moir DT, Bowlin TL, Bavari S.

J Antibiot (Tokyo). 2013 Jan;66(1):47-9. doi: 10.1038/ja.2012.93. Epub 2012 Nov 14. No abstract available.

PMID:
23149517
25.

A study on the thoron sensitivity of radon detectors available to Canadians.

Chen J, Moir D.

J Radiol Prot. 2012 Dec;32(4):419-25. doi: 10.1088/0952-4746/32/4/419. Epub 2012 Oct 3.

PMID:
23031835
26.

Canadian population risk of radon induced lung cancer: a re-assessment based on the recent cross-Canada radon survey.

Chen J, Moir D, Whyte J.

Radiat Prot Dosimetry. 2012 Nov;152(1-3):9-13. doi: 10.1093/rpd/ncs147. Epub 2012 Aug 8.

27.

New classes of antibiotics.

Moir DT, Opperman TJ, Butler MM, Bowlin TL.

Curr Opin Pharmacol. 2012 Oct;12(5):535-44. doi: 10.1016/j.coph.2012.07.004. Epub 2012 Jul 26. Review.

PMID:
22841284
28.

The concept of equivalent radon concentration for practical consideration of indoor exposure to thoron.

Chen J, Moir D.

Int J Environ Res Public Health. 2012 Jan;9(1):286-93. doi: 10.3390/ijerph9010286. Epub 2012 Jan 18.

29.

Soil radon measurements in the Canadian cities.

Chen J, Moir D, MacLellan K, Leigh E, Nunez D, Murphy S, Ford K.

Radiat Prot Dosimetry. 2012 Aug;151(1):172-4. doi: 10.1093/rpd/ncr442. Epub 2011 Nov 28.

PMID:
22128363
30.

Assessment of test duration effect in indoor radon measurement by Monte Carlo simulations.

Chen J, Moir D.

Radiat Prot Dosimetry. 2012 Jun;150(2):248-58. doi: 10.1093/rpd/ncr396. Epub 2011 Oct 14.

PMID:
22003181
31.

Achievements and current activities of the Canadian radon program.

Chen J, Ford K, Whyte J, Bush K, Moir D, Cornett J.

Radiat Prot Dosimetry. 2011 Jul;146(1-3):14-8. doi: 10.1093/rpd/ncr096.

PMID:
21729938
32.

Determination of thoron equilibrium factor from simultaneous long-term thoron and its progeny measurements.

Chen J, Moir D, Sorimachi A, Janik M, Tokonami S.

Radiat Prot Dosimetry. 2012 Apr;149(2):155-8. doi: 10.1093/rpd/ncr228. Epub 2011 May 31.

PMID:
21632587
33.

Development and application of a cellular, gain-of-signal, bioluminescent reporter screen for inhibitors of type II secretion in Pseudomonas aeruginosa and Burkholderia pseudomallei.

Moir DT, Di M, Wong E, Moore RA, Schweizer HP, Woods DE, Bowlin TL.

J Biomol Screen. 2011 Aug;16(7):694-705. doi: 10.1177/1087057111408605. Epub 2011 May 20.

34.

Identification of a small-molecule entry inhibitor for filoviruses.

Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL.

J Virol. 2011 Apr;85(7):3106-19. doi: 10.1128/JVI.01456-10. Epub 2011 Jan 26.

35.

An update on thoron exposure in Canada with simultaneous ²²²Rn and ²²⁰Rn measurements in Fredericton and Halifax.

Chen J, Moir D, Pronk T, Goodwin T, Janik M, Tokonami S.

Radiat Prot Dosimetry. 2011 Nov;147(4):541-7. doi: 10.1093/rpd/ncq567. Epub 2011 Jan 6.

PMID:
21216734
36.

Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication.

Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL.

Molecules. 2010 Dec 30;16(1):202-20. doi: 10.3390/molecules16010202. Review.

37.

The design of Radiation Accident Registry.

Chen J, Seely B, Bergman L, Moir D.

Radiat Prot Dosimetry. 2011 Mar;144(1-4):551-4. doi: 10.1093/rpd/ncq421. Epub 2010 Nov 25.

PMID:
21112894
38.

Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone Pharmacophore.

Burnett JC, Li B, Pai R, Cardinale SC, Butler MM, Peet NP, Moir D, Bavari S, Bowlin T.

Open Access Bioinformatics. 2010 Apr 1;2010(2):11-18.

39.

Preliminary assessment of thoron exposure in Canada.

Chen J, Dessau JC, Frenette E, Moir D, Cornett RJ.

Radiat Prot Dosimetry. 2010 Oct;141(4):322-7. doi: 10.1093/rpd/ncq226.

PMID:
20966201
40.

Considerations and preliminary design of patient exposure registry.

Chen J, Moir D, Cornett J.

Radiat Prot Dosimetry. 2010 Dec;142(2-4):255-64. doi: 10.1093/rpd/ncq280. Epub 2010 Oct 6.

PMID:
20926510
41.

Characteristics of thoron and thoron progeny in Canadian homes.

Chen J, Moir D, Sorimachi A, Tokonami S.

Radiat Environ Biophys. 2011 Mar;50(1):85-9. doi: 10.1007/s00411-010-0338-5. Epub 2010 Sep 25.

PMID:
20872008
42.

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.

Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Cabes M, Lawrie CH, Moir D, Hatton C, Banham AH, Pulford K.

Haematologica. 2011 Jan;96(1):78-86. doi: 10.3324/haematol.2010.028241. Epub 2010 Sep 17.

43.

Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.

Butler MM, Williams JD, Peet NP, Moir DT, Panchal RG, Bavari S, Shinabarger DL, Bowlin TL.

Antimicrob Agents Chemother. 2010 Sep;54(9):3974-7. doi: 10.1128/AAC.00484-10. Epub 2010 Jul 12.

44.

An estimation of the annual effective dose to the Canadian population from medical CT examinations.

Chen J, Moir D.

J Radiol Prot. 2010 Jun;30(2):131-7. doi: 10.1088/0952-4746/30/2/002. Epub 2010 Jun 9.

PMID:
20530855
45.

Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.

Opperman TJ, Williams JD, Houseweart C, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.

Bioorg Med Chem. 2010 Mar 15;18(6):2123-2130. doi: 10.1016/j.bmc.2010.02.005. Epub 2010 Feb 10.

PMID:
20188576
46.

Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.

Aiello D, Williams JD, Majgier-Baranowska H, Patel I, Peet NP, Huang J, Lory S, Bowlin TL, Moir DT.

Antimicrob Agents Chemother. 2010 May;54(5):1988-99. doi: 10.1128/AAC.01598-09. Epub 2010 Feb 22.

47.

An updated assessment of radon exposure in Canada.

Chen J, Moir D.

Radiat Prot Dosimetry. 2010 Jul;140(2):166-70. doi: 10.1093/rpd/ncq046. Epub 2010 Feb 19.

PMID:
20172936
48.

Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.

Li B, Pai R, Cardinale SC, Butler MM, Peet NP, Moir DT, Bavari S, Bowlin TL.

J Med Chem. 2010 Mar 11;53(5):2264-76. doi: 10.1021/jm901852f.

49.

Barcoding bacterial cells: A SERS based methodology for pathogen identification.

Patel IS, Premasiri WR, Moir DT, Ziegler LD.

J Raman Spectrosc. 2008 Nov;39(11):1660-1672.

50.

Aryl rhodanines specifically inhibit staphylococcal and enterococcal biofilm formation.

Opperman TJ, Kwasny SM, Williams JD, Khan AR, Peet NP, Moir DT, Bowlin TL.

Antimicrob Agents Chemother. 2009 Oct;53(10):4357-67. doi: 10.1128/AAC.00077-09. Epub 2009 Aug 3.

Supplemental Content

Support Center